Key Segmentation
By Indication
-
ATTR‑CM (Transthyretin Amyloid Cardiomyopathy)
-
ATTR‑PN (Transthyretin Amyloid Polyneuropathy)
-
Off‑label/expanded use
-
Combination therapy potential
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Specialty Pharmacies
-
Online Pharmacies
-
Others
By Payer / Reimbursement Type
-
Public insurance
-
Private insurance
-
Out of pocket/self pay
-
Patient assistance programs
-
Others
By Patient Type / Care Setting
-
Diagnosed ATTR‑CM patients
-
Diagnosed ATTR‑PN patients
-
Undiagnosed/late‑diagnosis patients
-
Clinical trial participants / expanded access programs
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated with a 42.54% share in 2025, while Asia-Pacific is the fastest-growing region, expected to expand at a CAGR of 17.43% during 2026–2035.
Diagnosed ATTR‑CM patients dominated with a 65.86% share in 2025, while Undiagnosed/late‑diagnosis patients are projected to grow at the fastest CAGR of 18.49% during 2026–2035.
Growth is driven by rising diagnosis of transthyretin amyloidosis and cardiomyopathy cases and patient advocacy initiatives, strong adoption of transthyretin stabilizers alongside emerging RNA‑based and antibody therapies.
The market is valued at USD 2.02 Billion in 2025 and is projected to reach USD 8.34 Billion by 2035.
The Vyndaqel Market is projected to grow at a CAGR of 15.39% during 2026–2035.